Article
A Swedish study examine the genetic contribution to various rheumatic/musculoskeletal diseases (RMDs) and showed that osteoarthritis (OA) had a large heritability compared with other RMDs.
All News
Article
Dr. Jack Cush imparts his new New Year's Resolutions for 2024 and also reviews the news and journal reports from the past week on RheumNow.com.
Article
An international task force of 13 European experts have developed evidence-based points to consider regarding the cost-effective use of biological and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in the treatment of inflammatory rheumatic diseases (including rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis).
Dr. John Cush
Tweet
QD Clinic - Rituximab Dosing in RA
Rituximab Fixed Interval vs On-Demand Dosing in RA.
https://t.co/z0Vvgh0xI5 https://t.co/0nGxt344G9
Dr. John Cush
Tweet
Life expectancy in RA? Taiwan insurance claims data shows life expectancy after an RA Dx was 26.3 yrs, w/ mean loss of 5 yrs. Women lived 1–2 yrs longer than men. https://t.co/Z5PqWZX94V https://t.co/RKZNDxPUd3
Dr. John Cush
Tweet
Experience the Future of Rheumatology at RheumNow Live 2024, just three weeks away!
Don't miss out – secure your spot today for an unforgettable journey into the latest advancements and insights.
https://t.co/HN8ErCpSMb https://t.co/kCYD7Hbhxx
Dr. John Cush
Tweet
Cross-sectional study of 307 RA pts, 49 (16%) used psychotropic meds and 70 (23%) had at least one fall per year. RA on psychotropic meds had double the rate of falls (39% vs 20%). w/ an adjusted incidence rate ratio, 1.63. (p = 0.02). https://t.co/D1lhZj3he3
Dr. John Cush
Tweet
Do I have Arthritis?
How I handle this frequent curbside consult question...
https://t.co/uX6MUfy59w https://t.co/kYviOhcLQj
Dr. John Cush
Tweet
Marketscan claims data shows Frailty as predictor for serious infxn in RA pts Rx w/ b/tsDMARDs. Among 57,980 RA pts (age 48 yrs), 6% were "frail" - this assoc w/ increased risk of serious infections (aHR 1.5) & inpatient hosp (1.4)https://t.co/cvcqE3KQmV https://t.co/We9uwMdt5Y
Dr. John Cush
Tweet
FDA Approves the first Actemra biosimilar- called tocilizumab-bavi (Tofidence) or BIIB800 (during development). This IV FORMULATION is approved for use in active RA, polyarticular JIA and systemic JIA. https://t.co/XdQ3D2McTF https://t.co/wnusToyZTG https://t.co/w8ooCCGrI0…
Dr. John Cush
Tweet
Rheumatoid vasculitis (RV) metanalysis: RV decreased from 9.1 (1988-2000) to 3.9 (2001-2010) per million. RV risk increased w/ smoking, disease duration, seropositivity, males, HLA-DRB104, HLA-C3. Common: skin (65–88%), CNS(35–63%), cardiac (33%) https://t.co/gBxd9EIvo2 https://t.co/NFMSkeAq5d
Dr. John Cush
Tweet
A double-blind, sham-controlled RCT of auricular vagus nerve stimulation (VNS) showed NO meaningful improvement in 101 RA completers. @week 12, ACR20 was 25% for VNS vs 27% for sham (NS). Also NS was change in DAS28-CRP (–0.95 vs –0.66)(p 0.06) https://t.co/n4e564a3gN https://t.co/mnVliEuafK
Dr. John Cush
Tweet
RheumNow Live 2024 is nearly here!
Among our 25 speakers, Dr. Weber will cover Cardio-Rheumatology Clinic - Identifying CV Risks. Dr. Guma will cover Nutrition in RA. Dr. El Gabalaway will cover the Prevention of RA, all in a session on Success in RA.
https://t.co/5kq9KReEsJ https://t.co/L2GiR8Upqn
Dr. John Cush
Tweet
Best of 2023: Cost-Effective Use of Biological and Targeted Synthetic DMARDs
An international task force of 13 European experts have developed evidence-based points to consider regarding the cost-effective use of biological and targeted synthetic disease.
https://t.co/UAlpww3fmi https://t.co/NpkTgwDuRl
Dr. John Cush
Tweet
Time to Risk Stratify Methotrexate Lab Monitoring? A longitudinal cohort analysis has developed a prognostic model that informs a risk stratified approach to monitoring blood tests during long term methotrexate (MTX) therapy. https://t.co/R2TOzSO6cx https://t.co/XY3XEkSCT6
Dr. John Cush
Tweet
RA and cancer risk in the biologic era
RA is known to be historically associated with site specific cancers, especially lung skin and lymphomas. This risk was described as likely to be supported by chronic systemic inflammation before the biologic era.
https://t.co/ZOWFKTg3l3 https://t.co/1VLWgxVb0W
Dr. John Cush
Tweet
STOP-RA study on HCQ preventing RA... HCQ did NOT prevent RA development in pre-RA pts
#RNL2023 https://t.co/BqZlajMOLK https://t.co/Omui3LWiPi
Dr. John Cush
Tweet
Analysis of 14,958 RA pts in Japans National Database of Rheumatic Diseases (NinJa) shows women had higher DAS28-ESR values than males, despite no obvious difference in other indices or disease activity categories. https://t.co/bLFmRdulCw
Dr. John Cush
Tweet
A Danish national registry study compared RA pts taking JAKi (n 875) and bDMARDs (n 4247). They found similar rates of subsequent cancers (14.4 vs 12.9/ per 1000 PYRS); with a nonsignificant risk (HR1.41; CI 0.76, 2.37) https://t.co/LNIqQxQFKK
Dr. John Cush
Tweet
FDA Approves the first Actemra biosimilar- called tocilizumab-bavi (Tofidence) or BIIB800 (during development). This IV FORMULATION is approved for use in active RA, polyarticular JIA and systemic JIA. https://t.co/AJD4uOS9hz https://t.co/8bmyTUWyFs https://t.co/6IYjk0XUJq https://t.co/OfjdvJZciB
